Key Takeaways Eli Lilly agreed to acquire Orna Therapeutics in a $2.4B deal with milestone-based payments.LLY will gain an in vivo CAR-T pipeline, including ORN-252, for B-cell-driven autoimmune diseases.Eli Lilly will also acquire Orna's circular RNA platform to support pipeline diversification.Eli Lilly (LLY) announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both upfront consid ...